13F Holdings
中文EN

NERV Minerva Neurosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1598646 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,973.5%
TTM EPS YoY-1,728.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-460.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets187.3%
Debt / equity—
Current ratio33.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.11x
Accruals ratio-410.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—$0$0$0$0
R&D expense$5.76M$11.90M$12.71M$14.65M$32.04M
SG&A expense$9.34M$9.95M$10.41M$10.58M$13.33M
Operating income-$15.10M-$21.85M-$23.12M-$25.23M-$45.37M
Pretax income———-$32.11M-$51.71M
Income tax————-$1.80M
Net income-$293.42M$1.44M-$30.01M-$32.11M-$49.91M
EBITDA-$15.10M-$21.84M-$23.11M——
EPS (basic)-34.670.19-4.61-6.01-9.35
EPS (diluted)-34.670.19-4.61-6.01-9.35
Weighted avg. shares (diluted)8.46M7.57M6.51M5.34M5.34M
Balance sheet
Cash & equivalents$82.30M$21.36M$40.91M$36.09M$60.76M
Current assets$83.10M$22.27M$42.00M$40.16M$62.20M
PP&E, net$0$5,442$10,884$16,326—
Goodwill$14.87M$14.87M$14.87M$14.87M$14.87M
Total assets$97.97M$37.14M$56.90M$55.09M$77.12M
Current liabilities$2.29M$2.84M$3.34M$1.38M$2.82M
Total liabilities$233.76M$62.84M$85.36M$75.11M$69.15M
Shareholders' equity-$140.75M-$25.69M-$28.46M-$20.02M$7.98M
Shares outstanding43.27M6.99M6.99M5.34M5.34M
Cash flow statement
Operating cash flow-$13.51M-$19.55M-$14.78M-$24.65M-$24.60M
Capital expenditure———$16,326—
Free cash flow———-$24.66M—
Investing cash flow$0$0$0-$16,326—
Financing cash flow$74.45M—$19.60M-$5$60.00M
Depreciation & amortization$5,442$5,442$5,442——
Stock-based compensation$1.33M$1.33M$1.97M$4.11M$5.22M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.